Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CATHY B BARNES

Allopathic & Osteopathic Physicians Family Medicine

NPI
1821089756
CMS profile
309044
Location
TRINITY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$2,414.87

43 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,786.98 9
Food and Beverage $627.89 34

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $2,352.21 42
Janssen Pharmaceuticals, Inc $62.66 1

Page 1 of 1; records 1–43 of 43 matching records. This page contains 43 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CATHY B BARNES

NPI 1821089756 · CMS profile ID 309044

Allopathic & Osteopathic Physicians / Family Medicine

TRINITY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–43 of 43 matching records. This page contains 43 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1821089756?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CATHY B BARNES, NPI 1821089756, CMS profile ID 309044. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–43 of 43 matching records. This page contains 43 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1821089756?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). CATHY B BARNES, NPI 1821089756, CMS profile ID 309044. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–43 of 43 matching records. This page contains 43 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1821089756?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
CATHY B BARNES, NPI 1821089756, CMS profile ID 309044, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–43 of 43 matching records. This page contains 43 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1821089756?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

43 matching records · $2,414.87 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 43 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–43 of 43.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $41.1003/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728357795 CMS
Eli Lilly and Company $95.6303/24/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728381709 CMS
Eli Lilly and Company $2.9903/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728357799 CMS
Eli Lilly and Company $61.7503/05/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728357801 CMS
Eli Lilly and Company $83.3003/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728361219 CMS
Eli Lilly and Company $0.9503/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728361221 CMS
Eli Lilly and Company $4.8603/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728361223 CMS
Eli Lilly and Company $44.2003/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728361225 CMS
Eli Lilly and Company $13.6003/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728364665 CMS
Eli Lilly and Company $5.9503/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728364667 CMS
Eli Lilly and Company $20.8303/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728368115 CMS
Eli Lilly and Company $1.0403/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728368117 CMS
Eli Lilly and Company $13.0003/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728371577 CMS
Eli Lilly and Company $9.1603/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728374935 CMS
Eli Lilly and Company $2.9903/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728374937 CMS
Eli Lilly and Company $23.8003/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728378509 CMS
Eli Lilly and Company $11.0503/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728378511 CMS
Eli Lilly and Company $1.9003/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728381711 CMS
Eli Lilly and Company $248.0003/05/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753917065 CMS
Eli Lilly and Company $606.6003/04/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728357793 CMS
Eli Lilly and Company $23.3803/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728357797 CMS
Eli Lilly and Company $1.9003/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728361217 CMS
Eli Lilly and Company $4.6803/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728364661 CMS
Eli Lilly and Company $7.9603/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728364663 CMS
Eli Lilly and Company $0.9803/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728368111 CMS
Eli Lilly and Company $2.9803/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728368113 CMS
Eli Lilly and Company $240.0003/03/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728371565 CMS
Eli Lilly and Company $10.2903/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728371567 CMS
Eli Lilly and Company $93.5003/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728371569 CMS
Eli Lilly and Company $4.8603/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728371571 CMS
Eli Lilly and Company $0.9503/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728371573 CMS
Eli Lilly and Company $2.9803/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728371575 CMS
Eli Lilly and Company $157.0003/03/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728374933 CMS
Eli Lilly and Company $23.8003/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728378501 CMS
Eli Lilly and Company $5.9503/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728378503 CMS
Eli Lilly and Company $11.9003/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728378505 CMS
Eli Lilly and Company $65.0003/03/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728378507 CMS
Eli Lilly and Company $33.1503/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728381701 CMS
Eli Lilly and Company $44.2003/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728381703 CMS
Eli Lilly and Company $11.0503/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728381705 CMS
Eli Lilly and Company $65.0003/03/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728381707 CMS
Eli Lilly and Company $248.0003/03/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753916543 CMS
Janssen Pharmaceuticals, Inc $62.6602/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719071873 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $242.96 3
PY2020 $2,414.87 43
PY2021 $102.51 1
PY2022 $81.28 1
PY2024 $1,292.30 10
PY2025 $1,335.09 13

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,205,743.80 119
PY2024 Recipient $34,906.00 2
PY2024 Principal investigator $2,451,942.71 49
PY2023 Recipient $2,790.56 3
PY2023 Principal investigator $2,713,362.43 33
PY2022 Recipient $28,555.00 4
PY2022 Principal investigator $1,298,287.06 112
PY2021 Principal investigator $858,224.34 839
PY2020 Recipient $142.50 1
PY2020 Principal investigator $353,224.47 119
PY2019 Recipient $12,826.75 13
PY2019 Principal investigator $389,491.61 41

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eli Lilly and Company $30,757.00 12/24/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1137367539
Principal investigator 1 Amgen Inc. $3,170.00 12/04/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH LLC
DAZ-301 P3 DAZ Efficacy/Safety in Mod-Severe SS No dispute reported 06/30/2026 1096310443
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $2,500.00 11/20/2024 Non-covered Recipient Entity
Suncoast Clinical Research Llc
LX9211 No dispute reported 06/30/2026 1081187920
Principal investigator 1 ModernaTX, Inc. $75.13 11/19/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147180577
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $23,643.27 11/01/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH NEW PORT RICHEY
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1095482636
Principal investigator 1 ModernaTX, Inc. $75.13 10/31/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147180571
Principal investigator 1 Eli Lilly and Company $3,540.60 10/28/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1137366995
Principal investigator 1 ModernaTX, Inc. $102.45 10/22/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147180569
Principal investigator 1 Eli Lilly and Company $513.01 10/20/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137366979
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $23,128.20 10/18/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH INC
LX9211 No dispute reported 06/30/2026 1081189296
Principal investigator 1 Chiesi USA, Inc. $1,000.00 10/02/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148223478
Principal investigator 1 ModernaTX, Inc. $399.12 10/02/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147180567
Principal investigator 1 Novartis Pharmaceuticals Corporation $18,912.96 09/30/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse No dispute reported 06/30/2026 1089698625
Principal investigator 1 Eli Lilly and Company $3,235.51 09/15/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1137368364
Recipient Eli Lilly and Company $23,982.00 09/11/2024 Covered Recipient Physician A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1137346612
Recipient Eli Lilly and Company $10,924.00 09/11/2024 Covered Recipient Physician A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137346852
Principal investigator 1 Eli Lilly and Company $302,322.00 08/28/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY No dispute reported 06/30/2026 1137366981
Principal investigator 1 AstraZeneca Pharmaceuticals LP $20,742.60 08/23/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1110841422
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $166.00 08/21/2024 Non-covered Recipient Entity
Suncoast Clinical Research Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1081188742
Principal investigator 1 Eli Lilly and Company $229,756.00 07/23/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137366997
Principal investigator 1 Eli Lilly and Company $79,273.00 07/23/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137367537
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $92.00 06/26/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH INC
LX9211.1-204-DPN No dispute reported 06/30/2026 1081188986
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $188.00 06/14/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH INC
LX9211.1-204-DPN No dispute reported 06/30/2026 1081187752
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $92.00 06/12/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH INC
LX9211.1-204-DPN No dispute reported 06/30/2026 1081187748
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $116,916.87 05/28/2024 Non-covered Recipient Entity
Suncoast Clinical Research
Phase 2 PoC in Early AD Patients - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer s Disease (TargetT No dispute reported 06/30/2026 1123480010
Principal investigator 1 Amgen Inc. $3,508.38 04/10/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH INC - CLINEDGE - PPDS
DAZ-301 P3 DAZ Efficacy/Safety in Mod-Severe SS No dispute reported 06/30/2026 1096310441
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,710.41 03/29/2024 Non-covered Recipient Entity
Advarra Dba Schulman Associates Irb
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease (TargetTau-1) No dispute reported 06/30/2026 1123475109
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,339.00 03/29/2024 Non-covered Recipient Entity
WIRB COPERNICUS GROUP INC
LX9211.1-204-DPN No dispute reported 06/30/2026 1081188036
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $150.00 03/29/2024 Non-covered Recipient Entity
WIRB COPERNICUS GROUP INC
LX9211.1-204-DPN No dispute reported 06/30/2026 1081188046
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $150.00 03/29/2024 Non-covered Recipient Entity
WIRB COPERNICUS GROUP INC
LX9211.1-204-DPN No dispute reported 06/30/2026 1081188052
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $150.00 03/29/2024 Non-covered Recipient Entity
WIRB COPERNICUS GROUP INC
LX9211.1-204-DPN No dispute reported 06/30/2026 1081188062
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $150.00 03/29/2024 Non-covered Recipient Entity
WIRB COPERNICUS GROUP INC
LX9211.1-204-DPN No dispute reported 06/30/2026 1081188242
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $150.00 03/29/2024 Non-covered Recipient Entity
WIRB COPERNICUS GROUP INC
LX9211.1-204-DPN No dispute reported 06/30/2026 1081188252
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $500.00 03/29/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH INC
LX9211.1-204-DPN No dispute reported 06/30/2026 1081188342
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $600.00 03/29/2024 Non-covered Recipient Entity
WIRB COPERNICUS GROUP INC
LX9211.1-204-DPN No dispute reported 06/30/2026 1081188348
Principal investigator 1 Eli Lilly and Company $2,842.40 01/31/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1137366989
Principal investigator 1 Eli Lilly and Company $1,794.80 01/29/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137366985
Principal investigator 1 Eli Lilly and Company $11,234.59 01/24/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137367313
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $536.00 01/24/2024 Non-covered Recipient Entity
WIRB COPERNICUS GROUP INC
LX9211.1-204-DPN No dispute reported 06/30/2026 1081187648
Principal investigator 1 Eli Lilly and Company $13,587.25 01/18/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY No dispute reported 06/30/2026 1137368360
Principal investigator 1 Eli Lilly and Company $13,778.10 01/17/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137367541
Principal investigator 1 Eli Lilly and Company $2,637.04 01/09/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137366987
Principal investigator 1 Eli Lilly and Company $28,503.00 01/09/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) No dispute reported 06/30/2026 1137368698
Principal investigator 1 Eli Lilly and Company $643.04 01/09/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) No dispute reported 06/30/2026 1137368700
Principal investigator 1 Eli Lilly and Company $6,168.85 01/09/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137368702
Principal investigator 1 Amgen Inc. $9,150.00 01/04/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH INC
DAZ-301 P3 DAZ Efficacy/Safety in Mod-Severe SS No dispute reported 06/30/2026 1096310439
Principal investigator 1 Eli Lilly and Company $95,216.00 01/02/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137367311
Principal investigator 1 Eli Lilly and Company $103,584.00 01/02/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137367851
Principal investigator 1 Eli Lilly and Company $186,650.00 01/02/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1137368008
Principal investigator 1 Eli Lilly and Company $772,819.00 01/02/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137368692
Principal investigator 1 Eli Lilly and Company $330,790.00 01/02/2024 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1137368694